Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: richardred who wrote (1822)	4/30/2005 2:15:17 PM
From: arnie h	Read Replies (2) \| Respond to of 2173

You make a good point. As I recall, their exercise price was in the low $18s. If the price got slammed for a technical reason, it was probably because of the need for 2 injections a day as an adjuvant rather than a stand alone therapy. Most Type 2 patients on pills are quite familiar with needle pricks from their glucose tests. It doesn't seem all that much of a deal to me for the 2 injections assuming the pens work smartly. Analysts seem to think things will always remain the same and the companies doing the work will be passive and not respond to the challenges. With Lily, the leading company in diabetes control, as the partner; I would expect response will go well and they should get into a good position for stand alone approval within a reasonable time period. Also this from the Amylin web site "If approved, Exenatide will be administered as a fixed-dose injection using a pen / cartridge delivery system. Longer-term, the aim is to have a long-acting, sustained release injection that can be given once a month. A long-acting release formulation of Exenatide (Exenatide LAR) is in the early stages of development.". I might get a bit more or take a shot on a call for '07. There could be a lot of volatility near term as funds and institutions decide what to do.